Skip to main content
Top

Open Access 18-02-2024 | Human Papillomavirus | Original Paper

Performance of urine samples compared to cervical samples for detection of precancer lesions among HPV-positive women attending colposcopy clinic in Mexico City

Authors: Joacim Meneses-León, Sonia Hernández-Salazar, Leticia Torres-Ibarra, Rubí Hernández-López, Berenice Rivera-Paredez, Karina Robles-Rivera, Eduardo Lazcano-Ponce, Alba García-Vera, Mélany Godínez-Pérez, Leith León-Maldonado, Jorge Salmerón

Published in: Cancer Causes & Control

Login to get access

Abstract

Background

High-risk human papillomavirus (hrHPV) detection in self-collected urine samples (SeCUS) may be a promising alternative for cervical cancer screening because of its greater acceptability, as long as it can offer comparable sensitivity to clinician-collected cervical samples (CCoS) for detecting precancer lesions.

Objective

To evaluate the performance of the SeCUS compared to that of the CCoS for cervical intraepithelial neoplasia grade 3 (CIN3) detection among hrHPV-positive women receiving colposcopy in Mexico City using different specific extended HPV typing procedures: HPV16/18, HPV16/18/35/39/68 or HPV16/18/35/39/68/31.

Methods

From March 2017 to August 2018, 4,158 female users of the cervical cancer screening program at Tlalpan Sanitary Jurisdiction in Mexico City were invited to participate in the FRIDA-Tlalpan study. All participants provided ≥ 30 mL of SeCUS, and then a CCoS was obtained with Cervex-Brush®, which was used for hrHPV typing. Participants who tested positive for hrHPV in CCoS were referred for colposcopy for diagnostic confirmation, and all SeCUS of these women were also tested for hrHPV typing.

Results

In total, 561 hrHPV-positive women were identified by CCoS via colposcopy, and 82.2% of the SeCUS of these women were also hrHPV positive. From both CCoS and SeCUS, 7 cases of CIN3 were detected. Considering HPV16/18 typing, CCoS and SeCUS detected 4 cases of CIN3, but after HPV16/18/35/39/68/31 extension typing, both CCoS and SeCUS detected all 7 of the CIN3 cases among the hrHPV-positive women.

Conclusions

Using extended hrHPV typing based on HPV16/18/35/39/68/31, our results suggest that the performance of SeCUS may be equivalent to that of CCoS for detecting CIN3 lesions. Although our results are inconclusive, they support the hypothesis that SeCUS may be an attractive alternative worthy of further research.
Appendix
Available only for authorised users
Literature
2.
go back to reference Crosbie EJ, Einstein MH, Franceschi S et al (2013) Human papillomavirus and cervical cancer. The Lancet 382(9895):889–899CrossRef Crosbie EJ, Einstein MH, Franceschi S et al (2013) Human papillomavirus and cervical cancer. The Lancet 382(9895):889–899CrossRef
4.
go back to reference Arbyn M, Smith SB, Temin S et al (2018) Detecting cervical precancer and reaching under screened women by using HPV testing on self samples: updated meta-analyses. BMJ 363:k4823CrossRefPubMedPubMedCentral Arbyn M, Smith SB, Temin S et al (2018) Detecting cervical precancer and reaching under screened women by using HPV testing on self samples: updated meta-analyses. BMJ 363:k4823CrossRefPubMedPubMedCentral
5.
go back to reference Daponte A, Michail G, Daponte AI et al (2021) Urine HPV in the context of genital and cervical cancer screening—an update of current literature. Cancers 13(7):1640CrossRefPubMedPubMedCentral Daponte A, Michail G, Daponte AI et al (2021) Urine HPV in the context of genital and cervical cancer screening—an update of current literature. Cancers 13(7):1640CrossRefPubMedPubMedCentral
7.
go back to reference Allen-Leigh B, Uribe-Zúñiga P, León-Maldonado L et al (2017) Barriers to HPV self-sampling and cytology among low-income indigenous women in rural areas of a middle-income setting: a qualitative study. BMC Cancer 17(1):734CrossRefPubMedPubMedCentral Allen-Leigh B, Uribe-Zúñiga P, León-Maldonado L et al (2017) Barriers to HPV self-sampling and cytology among low-income indigenous women in rural areas of a middle-income setting: a qualitative study. BMC Cancer 17(1):734CrossRefPubMedPubMedCentral
8.
go back to reference Verdoodt F, Jentschke M, Hillemanns P et al (2015) Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomized trials. Eur J Cancer 51(16):2375–2385CrossRefPubMed Verdoodt F, Jentschke M, Hillemanns P et al (2015) Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomized trials. Eur J Cancer 51(16):2375–2385CrossRefPubMed
9.
go back to reference Torres-Ibarra L, Lazcano-Ponce E, Franco EL et al (2016) Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex 58(2):197–210CrossRefPubMed Torres-Ibarra L, Lazcano-Ponce E, Franco EL et al (2016) Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica Mex 58(2):197–210CrossRefPubMed
10.
go back to reference Inturrisi F, Aitken CA, Melchers WJ et al (2021) Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Regional Health–Europe 11 Inturrisi F, Aitken CA, Melchers WJ et al (2021) Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Regional Health–Europe 11
11.
go back to reference Hernández-López R, Hermosillo L, León-Maldonado L et al (2021) Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women. PLoS ONE 16(7):e0254946CrossRefPubMedPubMedCentral Hernández-López R, Hermosillo L, León-Maldonado L et al (2021) Performance of an affordable urine self-sampling method for human papillomavirus detection in Mexican women. PLoS ONE 16(7):e0254946CrossRefPubMedPubMedCentral
12.
go back to reference Solomon D, Davey D, Kurman R et al (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16):2114–2119CrossRefPubMed Solomon D, Davey D, Kurman R et al (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287(16):2114–2119CrossRefPubMed
14.
go back to reference Van Keer S et al (2022) Analytical and clinical performance of extended HPV genotyping with BD Onclarity HPV assay in home-collected first-void urine: a diagnostic test accuracy study. J Clin Virol 155:105271CrossRefPubMed Van Keer S et al (2022) Analytical and clinical performance of extended HPV genotyping with BD Onclarity HPV assay in home-collected first-void urine: a diagnostic test accuracy study. J Clin Virol 155:105271CrossRefPubMed
15.
go back to reference Ramírez-Palacios P, Chen A, Flores YN et al (2020) Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus–positive women in Mexico. Cancer Cytopathol 128:715–724CrossRefPubMed Ramírez-Palacios P, Chen A, Flores YN et al (2020) Benefit of double-reading cytology smears as a triage strategy among high-risk human papillomavirus–positive women in Mexico. Cancer Cytopathol 128:715–724CrossRefPubMed
16.
go back to reference Bober P, Firment P, Sabo J (2021) Diagnostic test accuracy of first-void urine human papillomaviruses for presence cervical HPV in women: systematic review and meta-analysis. Int J Environ Res Public Health 18(24):13314CrossRefPubMedPubMedCentral Bober P, Firment P, Sabo J (2021) Diagnostic test accuracy of first-void urine human papillomaviruses for presence cervical HPV in women: systematic review and meta-analysis. Int J Environ Res Public Health 18(24):13314CrossRefPubMedPubMedCentral
17.
go back to reference Schiffman M, Castle PE, Jerónimo J et al (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907CrossRefPubMed Schiffman M, Castle PE, Jerónimo J et al (2007) Human papillomavirus and cervical cancer. Lancet 370:890–907CrossRefPubMed
18.
go back to reference Rodriguez AC, Schiffman M, Herrero R et al (2008) Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513–517CrossRefPubMed Rodriguez AC, Schiffman M, Herrero R et al (2008) Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513–517CrossRefPubMed
19.
go back to reference Stoler MH, Parvu V, Yanson K et al (2023) Risk stratification of HPV-positive results using extended genotyping and cytology: data from the baseline phase of the Onclarity trial. Gynecol Oncol 174:68–75CrossRefPubMed Stoler MH, Parvu V, Yanson K et al (2023) Risk stratification of HPV-positive results using extended genotyping and cytology: data from the baseline phase of the Onclarity trial. Gynecol Oncol 174:68–75CrossRefPubMed
21.
go back to reference Bornstein J, Bentley J, Bösze P et al (2012) 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 120(1):166–172CrossRefPubMed Bornstein J, Bentley J, Bösze P et al (2012) 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 120(1):166–172CrossRefPubMed
Metadata
Title
Performance of urine samples compared to cervical samples for detection of precancer lesions among HPV-positive women attending colposcopy clinic in Mexico City
Authors
Joacim Meneses-León
Sonia Hernández-Salazar
Leticia Torres-Ibarra
Rubí Hernández-López
Berenice Rivera-Paredez
Karina Robles-Rivera
Eduardo Lazcano-Ponce
Alba García-Vera
Mélany Godínez-Pérez
Leith León-Maldonado
Jorge Salmerón
Publication date
18-02-2024
Publisher
Springer International Publishing
Published in
Cancer Causes & Control
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-024-01852-w
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine